课题基金 / 基金详情

PNNL Proteome Characterization Center

PNNL Proteome Characterization Center
PNNL 蛋白质组表征中心
批准号:
9210313
负责人:
Tao Liu
金额:
$112.38万
依托单位国家:
美国
项目类别:
财政年份:
2016
资助国家:
美国
项目状态:
已结题
起止时间:
2016-09-21 至 2021-08-31

项目摘要

项目成果

Tao Liu的其他基金

相似基金

相关文献

中文摘要
翻译
项目总结 PNNL蛋白质组特征中心(PCC)的总体目标是整合基因组信息 利用蛋白质组学技术对蛋白质组和翻译后修饰进行综合表征 (PTMS)以及癌症信号网络中蛋白质的功能相互作用。作为项目控制委员会的一员 目前的临床蛋白质组肿瘤分析联盟(CPTAC)计划PNNL成功应用 先进的蛋白质组学能力和专业知识,可用于全面的蛋白质组学和磷蛋白质组学 来自癌症基因组图谱的卵巢高级别浆液性癌的特征,并已开发 新的质谱学方法有助于完整蛋白质的分析,低化学计量比的PTMS,以及 非常小的样本。计划中的PNNL PCC将在这些成就的基础上发展,并为 CPTAC网络通过表征CPTAC分配的多种新的肿瘤类型而成功,使用这两种 经过验证的标准化、多路复用的发现和目标确认性工作流,以及引入 适当改进蛋白质组测量的新技术和新平台。都是人类 将对NCI提供的生物制品和临床前模型进行分析。 Discovery Research Arm将全面描述蛋白质组和多个PTM组 应用先进蛋白质组学验证的人类生物标本和2-3例癌症的临床前样本 平台、集成的工作流程和信息学工具,使用高度多元化的等压标签和状态 最先进的高效液相色谱-串联质谱仪,可处理多达300个样品 每年。验证性研究部门将验证基因组变异对基因变化的影响 具有有效靶向蛋白质组平台的蛋白质组和PTM组(例如,多反应监测), 多肽标准和质量保证。多达100种高度特异的多重靶向蛋白质组学分析 每年将为验证性研究开发蛋白质和PTM,每次使用多达150个样本 年。我们还将在PNNL PCC上完善和验证几个发展战略和平台 利用我们在超快气相分离和小型气体分离等领域正在进行的技术开发 扩大样品分析平台和方法的规模,以进一步提高两者的吞吐量和灵敏度 发现和验证性研究。 PNNL PCC将与其他项目控制中心、蛋白质基因组数据分析中心和 CPTAC数据整合和生物信息学网络中的蛋白质基因组翻译研究中心 分析以及翻译应用程序。
英文摘要
PROJECT SUMMARY The overall objective of the PNNL Proteome Characterization Center (PCC) is to integrate genomic information with proteomic technologies to comprehensively characterize the proteome and post-translational modifications (PTMs) as well as the functional interaction of proteins in signaling networks in cancers. As one of the PCCs in the current Clinical Proteomic Tumor Analysis Consortium (CPTAC) program, PNNL successfully applied advanced proteomics capabilities and expertise to the comprehensive proteogenomic and phosphoproteomic characterization of ovarian high-grade serous carcinomas from The Cancer Genome Atlas, and has developed novel mass spectrometric approaches to facilitate the analysis of intact proteins, low stoichiometry PTMs, and extremely small samples. The planned PNNL PCC will build on these achievements and contribute to the success of the CPTAC network by characterizing multiple new tumor types assigned by CPTAC, using both the proven standardized, multiplexed discovery and targeted confirmatory workflows as well as introducing novel technologies and platforms, as appropriate, to improve proteomic measurements. Both human biospecimens and preclinical models provided by NCI will be analyzed. The Discovery Research Arm will comprehensively characterize the proteome and multiple PTM-omes in human biospecimens and preclinical samples of 2-3 cancers with the validated advanced proteomics platforms, integrated workflows and informatics tools, using highly multiplexed isobaric labeling and state-of- the-art liquid chromatography-tandem mass spectrometry instrumentation at a throughput of up to 300 samples per year. The Confirmatory Research Arm will verify the impact of genomic variation on the changes in proteome and PTM-omes with validated targeted proteomics platforms (e.g., multiple reaction monitoring), peptide standards and quality assurance. Up to 100 highly specific, multiplexed targeted proteomics assays for both proteins and PTMs will be developed each year for the confirmatory studies using up to 150 samples per year. We will also refine and validate several developmental strategies and platforms at the PNNL PCC leveraging our on-going technology development in areas such as ultrafast gas phase separations and small- sized sample analysis platforms and methodologies to further improve the throughput and sensitivity in both the discovery and confirmatory studies. The PNNL PCC will work closely with the other PCCs, Proteogenomic Data Analysis Centers and Proteogenomic Translational Research Centers in the CPTAC network on data integration and bioinformatics analysis, as well as translational applications.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Center for Advanced Multi-Omic Characterization of Cancer
Center for Advanced Multi-Omic Characterization of Cancer
Center for Advanced Multi-Omic Characterization of Cancer
Targeted therapy against TERT oncogene-rearranged neuroblastoma
  • 批准号:
    10452641
  • 项目类别:
  • 资助金额:
    $5.4万
  • 财政年份:
    2021
  • 负责人:
    Tao Liu
  • 依托单位:
海外基金